Skip to main content

Table 1 New approved drugs for the second-line treatment of patients with advanced NSCLC

From: Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the ‘panacea’ for all patients?

Reference

Patients

Histotype

Regimen

Response

Progression-free survival, months

Median overall survival, months

P

Reck et al. [3]

658

Adenocarcinoma

Docetaxel + nintedanib vs. docetaxel + placebo

4.7% vs. 3.6%

4.0 vs. 2.8

12.6 vs. 10.3

0.0359

Garon et al. [4]

1253

All histologies

Docetaxel + ramucirumab vs. docetaxel + placebo

23% vs. 14%

4.5 vs. 3.0

10.5 vs. 9.1

0.023

Brahmer et al [5]

272

Squamous

Nivolumab vs. docetaxel

20% vs. 9%

3.5 vs. 2.8

9.2 vs. 6.0

<0.001

Borghaei et al. [6]

582

Adenocarcinoma

Nivolumab vs. docetaxel

19% vs. 12%

2.3 vs. 4.2

12.2 vs. 9.4

0.002

Herbst et al. [7]

1034

All histologies

Pembrolizumab 2 mg/kg vs. pembrolizumab 10 mg/kg vs. docetaxel

18% vs. 18% vs. 9%

3.9 vs. 4.0 vs. 4.0

10.4 vs. 12.7 vs. 8.5

0.0008

< 0.0001

Rittmeyer et al. [8]

287

All histologies

Atezolizumab vs. docetaxel

14% vs. 13%

2.8 vs. 4.0

13.8 vs. 9.6

0.0003

Soria et al. [9]

795

Squamous

Afatinib vs. erlotinib

6% vs. 3%

2.6 vs. 1.9

7.9 vs. 6.8

0.0077